Research and Markets — Tinnitus — Pipeline Review

C

captzutter

Member
Author
Apr 24, 2013
3
Tinnitus Since
01/2013
#1
I ran across this: http://www.researchandmarkets.com/reports/2557648/tinnitus_pipeline_review_h1_2013#toc

The table of contents list the current companies that are pursuing tinnitus treatments, and the name of the drugs:

Novartis AG
Merz GmbH & Co. KGaA
Auris Medical AG
Synphora AB
NeuroSystec Corporation

neramexane mesylate
AM-101
BGG-492
gacyclidine
memantine hydrochloride

I hadn't heard of BGG-492 or gacyclidine before.
 
#3
I had never heard of Synphora either. Good find. Perhaps they'll be joining the clinical stage race soon. I do hope that we get some solid footing within the next 5 years.
 
#4
The Synphora solution
Noise-induced tinnitus generates reactive oxygen species (free radicals) damaging the neural structures which may be involved in tinnitus generation.

Acoustic trauma triggers a cochlear overstimulation which may cause an excess release of glutamate in the synapse between the inner hair cells and the auditory nerve. An up-regulation of NMDA glutamate receptors may also occur. Both processes occurring simultaneously may in turn lead to a massive Ca2+ release of and activation of pro-apoptotic signaling cascades in the spiral ganglion cells and ultimately cell death decreasing auditory nerve activity.

Latanoprost, and other prostaglandin PGF2α analogues, have been shown to a exert neuroprotective effect, e.g. against glutamate toxicity in retinal ganglion cells. This effect is independent of its effect of lowering intra-ocular pressure through activation of the uveoscleral outflow of ocular fluid. A potential suggested mechanism for its neuroprotective effect has been the suppression of Ca2+ and as a consequence apoptosis.

Salicylate-induced tinnitus has been suggested to be due to excessive arachidonic acid levels due to the blockade of COX1-2. The arachidonic acid would then potentiates the effect of glutamate causing a dysregulation of cochlear NMDA receptors. An alternative interpretation is that the reduced levels of cochlear prostaglandin following COX1-2 inhibition may elicit tinnitus assuming that endogenous PGF2α generated in the cochlea, is important for the normal physiologic hearing process.

All three examples provide appealing potential mechanisms of action and rationale for prostaglandin PF2α intervention in noise-induced tinnitus which is currently under evaluation.

http://en.wikipedia.org/wiki/Latanoprost



Study of BGG492 in Patients With Chronic Subjective Tinnitus
(I couldn't find the results of this study anywhere.)



Effects of extracochlear gacyclidine perfusion on tinnitus in humans: a case series.
Abstract
Gacyclidine, a non-competitive NMDA receptor antagonist, is a phencyclidine derivative with neuroprotective properties. It has been previously safely administered intravenously to acute traumatic brain-injured patients. Experiments in guinea pigs have shown that local administration of gacyclidine to the cochlea can suppress salicylate-induced tinnitus. Thus, we thought that patients with therapy-resistant sensorineural tinnitus might benefit from a local therapy with gacyclidine. As a compassionate treatment, we administered aqueous gacyclidine solution via a Durect RWmuCath(TM) into the round window niche in six patients with unilateral deafness associated with tinnitus. The response of each patient to the drug treatment was given a numerical value by the use of a visual analogue scale (VAS) on a scale of 0-10 for tinnitus intensity, where 0 represented no tinnitus and 10 represented unbearable tinnitus-intensity or -annoyance (subjective). After constant perfusion of gacyclidine for 40-63 h, four out of six patients experienced a temporary relief from their tinnitus. No serious side effects were recorded in any of the cases. Gacyclidine might present a potent drug for the suppression of sensorineural tinnitus in humans and therefore should be considered for future double-blinded, placebo-controlled clinical trials. For lasting effective treatment, controlled intracochlear and long-term delivery of the drug seems to be necessary. Further studies investigating the toxicological effects of gacyclidine intracochlear perfusion as well as different dosages and therapy durations are under way to ensure the safety of the drug for long-term human use and warrant clinical trials.
 
#7
James White said:
I didn't want to start a topic about that but do any of you know what happened to NeuroSystec ?

http://www.neurosystec.com < nice website ! lol :)

Their research looked promising as apparently gacyclidine worked quite well for tinnitus.
Click to expand...
I did research them last month. I don't believe they are still in business, but they just be could off the radar. They were developing a pump to deliver drugs to the inner ear. They had a clinical trial in Belgium and France, but it was terminated. This is usually not a good sign. But inner ear drug delivery systems, including pumps, are still a growing area. Even if NeuroSystec no longer exists, the researchers probably went to other companies also working on these technologies.

Here are some links:

http://clinicaltrials.gov/ct2/show/NCT00957788
http://www.corporationwiki.com/California/Valencia/neurosystec-corporation/44004527.aspx
http://www.sbir.gov/sbirsearch/detail/248021

Note: This is a California company. Why they went to Europe is interesting. Did they have financial connections in Europe? Or is the climate for clinical trials and drug approval superior in Europe? I do see one of their research partners is the Medical University of Hannover, which is located in Germany.
 
#8
They do exist, they are just building their website. As far as why they work in Europe more, I am not sure. Perhaps ENT clinics there are more willing to work on tinnitus research.
 
#9
Hudson said:
They do exist, they are just building their website.
Click to expand...

Well, that's welcomed information! :)

AM 101 uses the RWM for drug delivery; but, in the future, pumps will be used as you can better control the dosing.
 
#10
I believe their technology was a two pronged approach. I haven't read about them in a little while but I think they had a delivery system (the pump) that they had engineered, but were also working on a small molecule for treatment as well. I could never find any information about what the nature of their compound was though.
 
#11
The Medical University of Hannover, Germany, seems very active in tinnitus research, including their relationship with NeuroSystec. The University is also interested in inner ear delivery systems--again, the same as NeuroSystec. (See Markku's Gacyclidine citation) I wonder what relationship exists between researchers in each organization?

Anyway, inner ear delivery systems are exciting, new areas to treat tinnitus and inner ear diseases. Here are a two of several references:

http://www.ncbi.nlm.nih.gov/pubmed/22283653
http://www.ncbi.nlm.nih.gov/pubmed/22386561
 
#12
Hudson said:
I believe their technology was a two pronged approach. I haven't read about them in a little while but I think they had a delivery system (the pump) that they had engineered, but were also working on a small molecule for treatment as well. I could never find any information about what the nature of their compound was though.
Click to expand...
Yes, I think I found this drug, but there's not much information on it. This is from the ATA's site:

Tom Lobl, Ph.D.,Vice President of Research and Development for NeuroSystec, a company with the mission to relieve the suffering of patients with hearing and neurological diseases by combining therapeutics and delivery devices to provide new intervention tools for medicine. Also, improve therapeutic profile and reduce side effects through tissue-specific delivery of powerful CNS agents. Tom appears in over 30 publications and holds 15 patents/applications. He and his team are currently developing a novel drug for tinnitus, NST-001.

http://www.ata.org/ata-works
​
Can't wait for NeuroSystec's website to be updated and hopefully a pipeline listed.

​
 
#13
I actually find this very interesting, it fits into the engineering side of schooling that I've had. That's why I like the look of Sue Shore's lab at UM as well. Now I just need to get off my rear end and take the GRE....
 
#14
jazz said:
The Medical University of Hannover, Germany, seems very active in tinnitus research, including their relationship with NeuroSystec. The University is also interested in inner ear delivery systems--again, the same as NeuroSystec. (See Markku's Gacyclidine citation) I wonder what relationship exists between researchers in each organization?

Anyway, inner ear delivery systems are exciting, new areas to treat tinnitus and inner ear diseases. Here are a two of several references:

http://www.ncbi.nlm.nih.gov/pubmed/22283653
http://www.ncbi.nlm.nih.gov/pubmed/22386561
Click to expand...

From what i've looked up, Thomas Lobl now works for the Alfred Mann Foundation. The address is the exact same as NeuroSystec. Maybe they just ditched the Neurosystec name and are now inside the AMF. The AMF are interestingly enough a lot into these implants research but nothing on tinnitus on their website.

For the clinical trial, i could be wrong but someone french (have a look at the history changes) may have edited the status of the trial to "Terminated" as "Terminé" means "Completed" in french ;)
 
#15
James White said:
From what i've looked up, Thomas Lobl now works for the Alfred Mann Foundation. The address is the exact same as NeuroSystec. Maybe they just ditched the Neurosystec name and are now inside the AMF. The AMF are interestingly enough a lot into these implants research but nothing on tinnitus on their website.

For the clinical trial, i could be wrong but someone french (have a look at the history changes) may have edited the status of the trial to "Terminated" as "Terminé" means "Completed" in french ;)
Click to expand...

Thanks James for all this information!:) Let's hope "terminated" just meant "completed."

Several weeks ago, when I was critiquing the ATA's inability to fund itself adequately, I came across the AMF. It's a very interesting foundation. There's a potential tie in with tinnitus--especially since it often follows similar neurological pathways as chronic pain. Here's the AMF's research focus from their website:

Movement disorders, diabetes, limb loss and pain are all critical problems patients face today. The Alfred Mann Foundation's goal is to develop medical devices to help patients who have few medical options and advance that technology to the marketplace.
​
More importantly, they helped developed an improved version of a cochlear implant in 1986. AMF is serious money, but, like you, I don't see a current interest in inner ear drug delivery systems. But AMF is interested in electrical stimulation through implants for neuromuscular diseases. That might be why they hired Lobl. Or else he could be working in their chronic pain division, specifically their infusion pumps. Either way, this is a disappointment compared to Neurosystec's research.

But, then again, maybe AMF is interested in tinnitus, but the research is in its early stages. We can only hope. Because if AMF is interested, that could be a game changer for these types of devices.

Here's AMF's cochlear reference:

http://aemf.org/our-research/past-accomplishments/
 
#16
Thanks for your insight on AMF jazz.

I've just looked up for BGG492 from novartis, can't find much about it. Seems like they are still into it (2013) and also testing the compound for migraine and epilepsy.

On another side, have you looked at the synfora website ? Looks nice and maybe promising.
 
#17
James White said:
On another side, have you looked at the synfora website ? Looks nice and maybe promising.
Click to expand...
Yes, I did look into Synfora's interest in noise-induced tinnitus. They are targeting the NMDA receptors in the cochlea--the same as Auris Medical's AM 101. Auris's drug uses the Round Window Membrane to deliver their drug to the cochlea; I presume Synfora would do the same or similar. That's why developing pumps for drug delivery would be superior as you could better control dosing.

As you know, Auris is doing well with their drug. But, so far, the clinical trials are for tinnitus up to three months. But they are willing to extend it to a year in one upcoming phase III trial. This is promising.

Most researchers argue that chronic tinnitus ( > 6 or 12 months) is more challenging to treat than acute tinnitus (< 3 or 6 months). In chronic tinnitus, the brain has memorized the tinnitus sound. What's responsible for this memorization, researchers postulate, is the dorsal cochlear nucleus (DCN). The DCN serves a gatekeeper function for tinnitus in the brain. (For information on the DCN and tinnitus, see http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804917)

Synfora mentions the importance of treating tinnitus early--while it is still in the cochlea:

As times passes, the origin of sound-induced tinnitus undergoes a gradual relocation from the cochlea to the auditory brain, a process termed neural plasticity involving a form of re-programming of the brain.

This has implications for the timing of interventional treatments following noise-induced tinnitus. While the tinnitus is still of peripheral and cochlear origin it may still be amenable to treatment via intratympanic injection of drugs stabilizing the cochlear signaling. This may prevent the permanent plasticity changes occurring in the auditory brain which could translate into chronic tinnitus. (http://www.synphora.com/noise-induced-tinnitus/about-noise-induced-tinnitus.html)​

Auris also discusses this with their drug, even though they will expand their time frame. It appears the company feels the window between acute and chronic may be open longer than three months. (See http://www.aurismedical.com/p/therapies/am_101.php)

It's also possible--I'm just speculating--that people with chronic tinnitus will need a two-step approach. First, they will need to treat the damage in the cochlea, such as AM 101's treatment; second, they will need to address the neural correlates of tinnitus. Treating the latter might involve an oral medication or a neuromodulation modality. By addressing both injuries that result in the tinnitus precept, I'm sure the disorder will either be cured or rendered a non-issue, i.e., the noise disappears.

Of course, efficacious treatments for acute tinnitus are equally important for people with chronic tinnitus. Such treatments will prevent further damage from noise or trauma. (I don't know about hearing loss due to aging.) So the future does look bright! :)

About Novartis' drug: It might still be useful for people with tinnitus. Several anti-epileptic drugs have worked for some tinnitus sufferers, especially carbamazepine and neurontin. It's all about inhibiting overactive neural pathways. I'm sure the drug will be recommended "off label" for people with tinnitus once it's approved for epilepsy and migraine. As physicians develop tinnitus categories based on etiology, not just duration (acute or chronic), different types of treatment will be recommended. At least, this is what several researchers currently argue.

​
 
#18
Here is the reply i got from Tom Lobl of ex-NeuroSystec regarding gacyclidine :

Dear Mr. White,


Your enquiry to the AMF has been forwarded to me for response. Unfortunately, NeuroSystec has closed and its assets have been sold to another company. This company is now considering if they want to continue developing gacyclidine or not.

The "in construction" note on the website was added after closure when they wanted to take down the website but the future was not certain. It is still up because the former owners have forgotten about it.

The AMF unfortunately does not have any rights to develop this compound for tinnitus. I would recommend to the AMF that tinnitus is a good market to develop products for but that decision has not been made internally. In any event it could not develop gacyclidine.

I hope these comments answered your questions.

All the best,
Tom
Click to expand...
 
#19
Thanks James for investigating the NeuroSystec mystery. I and many others appreciate your efforts! :)

We'll have to keep monitoring the medical literature to see if gacyclidine appears in new pipeline. It would be a shame if this compound were not developed since it showed promise as a NMDA antagonist, like Auris' AM 101.
 
#20
Reviving an old post; but it should be mentioned that Pipeline Review H2 2014 is now out. http://www.researchandmarkets.com/reports/2988454/tinnitus-pipeline-review-h2-2014#adaptive

PR Web has a good overview section for subscribers: http://www.prweb.com/releases/tinnitus-pipeline-market/review-h2-2014-report/prweb12257731.htm

Of course the document is mainly for financial analysts and R & D insiders; seeing as it costs over 1000 USD to view online.

One interesting snap from the PR Web overview...

Tinnitus - Companies Involved in Therapeutics Development:

  • Merz Pharma GmbH & Co. KgaA
  • Auris Medical Holding AG
  • Knopp Biosciences LLC
  • Otonomy, Inc.
  • Sound Pharmaceuticals, Inc.
  • Synphora AB
  • Flexion Therapeutics, Inc.
  • Autifony Therapeutics Limited
  • AudioCure Pharma GmbH


Tinnitus - Drug Profiles:

  • neramexane mesylate
  • esketamine hydrochloride
  • latanoprost
  • SPI-1005
  • SPI-3005
  • AUT-00063
  • Gacyclidine
  • AUT-3
  • Acamprosate
  • Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus
  • AM-102
  • Drug to Activate KCNQ for Tinnitus
  • Small Molecules for Tinnitus
Click to expand...
 
#21
DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9rpzdv/tinnitus) has announced the addition of the "Tinnitus - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Flexion Therapeutics, Inc.
  • Knopp Biosciences LLC
  • Merz Pharma GmbH & Co. KgaA
  • Otonomy, Inc.
  • Sound Pharmaceuticals, Inc.
  • Synphora AB
Drug Profiles

  • acamprosate
  • AM-102
  • AUT-00063
  • AUT-3
  • Drug to Activate KCNQ for Tinnitus
  • esketamine hydrochloride
  • gacyclidine SR
  • latanoprost
  • neramexane mesylate
  • Small Molecules for Tinnitus
  • Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus
  • SPI-1005
  • SPI-3005
For more information visit http://www.researchandmarkets.com/research/9rpzdv/tinnitus


View source version on businesswire.com: http://www.businesswire.com/news/home/20150521005579/en/

Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
 
#22
ruben ruiz said:
DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9rpzdv/tinnitus) has announced the addition of the "Tinnitus - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Flexion Therapeutics, Inc.
  • Knopp Biosciences LLC
  • Merz Pharma GmbH & Co. KgaA
  • Otonomy, Inc.
  • Sound Pharmaceuticals, Inc.
  • Synphora AB
Drug Profiles

  • acamprosate
  • AM-102
  • AUT-00063
  • AUT-3
  • Drug to Activate KCNQ for Tinnitus
  • esketamine hydrochloride
  • gacyclidine SR
  • latanoprost
  • neramexane mesylate
  • Small Molecules for Tinnitus
  • Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus
  • SPI-1005
  • SPI-3005
For more information visit http://www.researchandmarkets.com/research/9rpzdv/tinnitus


View source version on businesswire.com: http://www.businesswire.com/news/home/20150521005579/en/

Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Click to expand...
Can someone here buy this review and share with us? It costs $2000

Interesting read?
 
#23

Attachments

  • Pharmacological approaches to the treatment of tinnitus.pdf
    141.6 KB · Views: 55
#25
Stumbled upon a fresh pipeline review about drugs in development by 8 different companies as of H1 2016:
http://www.researchandmarkets.com/research/fn3sgf/tinnitus

Below a summary of the companies and the compounds in development for your convenience (based on public information, don't have the report which costs a staggering €1808):

Companies
  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Flexion Therapeutics, Inc.
  • Knopp Biosciences LLC
  • Merz Pharma GmbH & Co. KgaA
  • Otonomy, Inc.
  • SciFluor Life Sciences, LLC
  • Sound Pharmaceuticals, Inc.
Compounds (based on the table of contents)
  • acamprosate calcium
  • AM-102
  • AUT-3 (still in research ?!?)
  • (no name) drug to Activate KCNQ for Tinnitus
  • esketamine hydrochloride
  • gacyclidine SR (probably oto-311)
  • neramexane mesylate
  • SF-0034
  • (no name) Small Molecules for Tinnitus
  • (no name) Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus
  • (no name) Small Molecules to Inhibit TNF-Alpha for Tinnitus
  • SPI-1005
  • SPI-3005
Conclusion: no big changes in comparison with previous post of @ruben ruiz for H1 2015.... bummer... this will take a very long time :arghh:
 
#26
I wonder how much progress has been made on the pump delivery system. A little off topic but I remember seeing something about one of the problems of stem cells was that there is no way to directly apply them to the inner ear. If something like a pump could effectively and safely deliver them to the inner ear I wonder if it would be more successful. I only say this because it seems as though the T specific drugs that are targeted at the ear are only for the acute stage.
 
#27
Mic said:
Stumbled upon a fresh pipeline review about drugs in development by 8 different companies as of H1 2016:
Click to expand...

Saw this, too. However, seeing that they still list Merz/Neramexane I wouldn't count on this report being up to date. I don't think it contains anything you can't find on Tinnitus Talk...
 

Log in or register to get the full forum benefits!

Register

Register on Tinnitus Talk for free!

Register Now

Similar threads

Hazel
Tinnitus Research Initiative (TRI) 2024 Conference
Replies
54
Views
12K
Research News
Stanley Pickle
Stanley Pickle
Bruhhhh
Taking Action Against Tinnitus: What Research to Invest Money in?
Replies
2
Views
135
Awareness & Fundraising
ZFire
ZFire
Hazel
Get 'Behind the Scenes' Insights from Tinnitus Research Conferences
Replies
10
Views
2K
Research News
DeanD
DeanD
I
Virtual Reality and Subjective Tinnitus (ReVA2)
Replies
1
Views
317
Research News
Nick47
N
Cmspgran
Sea Pharmaceuticals — Oral Neurotherapeutics for Tinnitus, Epilepsy, and ALS
Replies
2
Views
672
Research News
Kam75
Kam75
Top Bottom
Back
Forums
Members
Donate
Menu